title: AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
abstract: Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK cell activators, such as AFM13. This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
authors.forename: Jingjing
authors.initials: J
authors.lastname: Wu
authors.affiliation: Department of Hematology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
authors.forename: Jiaping
authors.initials: J
authors.lastname: Fu
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
authors.forename: Mingzhi
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. DELONG_LIU@NYMC.EDU.|Division of Hematology & Oncology, New York Medical College, Valhalla, NY, 10595, USA. DELONG_LIU@NYMC.EDU.
authors.forename: Delong
authors.initials: D
authors.lastname: Liu
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D017730:Ki-1 Antigen; D007694:Killer Cells, Natural
chemical_list: D000911:Antibodies, Monoclonal; D017730:Ki-1 Antigen